Eye treatment

2014-11-04 06:51:07

Share on StockTwits

There is a short-term trend in prices of companies, which activity concerns eye treatment. The aggregated price of Alimera Sciences and pSivida Corporation declined by 10.62 percent since last Thursday. There are two short summaries concerning fundamental data of both stocks:

Alimera:

  • Market Capitalization: $218.57 M
  • Price to Earnings: -5.74
  • Price to Book Value: 16.79
  • Return on Equity: -260.03%
  • Debt to Equity: 0.31
  • Current Ratio: 11.29

pSivida:

  • Market Capitalization: $128.71 M
  • Price to Earnings: -8.35
  • Price to Book Value: 8.02
  • Return on Equity: -89.54%
  • Debt to Equity: 0.14
  • Current Ratio: 9.08

It is easy to notice that the fundamental characteristics of both companies are similar.
There is no new information, which may have an impact on current price. The only info, which was published at the beginning of trend was about $25 Million payment under pSivida's out-license of drug (more info in article below). Probably the prices of those stocks bounced off resistance lines.

Opthalmic diseases

Drug Manufacturers - Major, Drug Delivery


Trend Strength: *****, Change: -10.62% Trend start: Thursday, 2014-10-30 13:15


Motif instruments:


ALIMPSDV

 

News and articles:

pSivida Corp. Announces First Quarter Fiscal 2015 Financial Results Release Date and Conference Call Information
Alimera Sciences to Release Third Quarter 2014 Results
ALIMERA SCIENCES INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
pSivida Corp. Receives $25 Million Milestone Payment

 

Check out out and subscribe to our YouTube channel!

Archive

2016 (7)

June (1)

April (4)

March (1)

January (1)

2015 (50)

October (1)

July (4)

June (20)

May (6)

April (1)

March (2)

February (12)

January (4)

2014 (33)

December (5)

November (20)

October (8)

 

Follow us on Twitter!


Help us improve
our site!